Given that breast cancer cell lines contain cells that exhibit properties of cancer stem-like cells, and cancer-initiating cells in primary human leukemia and glioblastoma are resistant to chemotherapy [31,32], we sought to determine whether cell line-derived CD44+/CD24-/ESA+ cells would also preferentially survive treatment with chemotherapeutic agents. This evidence concerns the gene CD44 and breast cancer.